// App-Quantinova.ai

351 : Pembrolizumab plus lenvatinib vs chemotherapy and lenvatinib monotherapy for recurrent/metastatic head and neck squamous cell carcinoma that progressed on platinum therapy and immunotherapy: LEAP-009

Researchers

Presenter

  • Kevin Harrington

Principal Investigators

  • Ezra Cohen

  • Lilian Siu

  • Danny Rischin

  • Lisa Licitra

  • Jan Vermorken

  • Quynh-Thu Le

  • Makoto Tahara

  • Jean-Pascal Machiels

  • Natalyn Hawk

  • Joy Ge

  • Behzad Bidadi

  • Ramona Swaby

  • Barbara Burtness

Medical Centers

  • The Institute of Cancer Research, London, UK

  • University of California, San Diego, Moores Cancer Center, La Jolla, CA

  • Universtiy Health Network, Toronto, ON, Canada

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

  • Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy

  • Antwerp University Hospital, Edegem, Belgium

  • National Cancer Center, EPOC, Chiba, Japan

  • Universite Catholique de Louvain, Bruxelles, Belgium

  • Eisai Inc, Woodcliff Lake, NJ

  • Merck & Co., Inc., Kenilworth, NJ

  • Yale Cancer Center, New Haven, CT

Locations

  • United Kingdom

  • United States

  • Canada

  • Australia

  • Italy

  • Belgium

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Squamous cell carcinoma of the head and neck

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • Pembrolizumab

  • Capecitabine

  • Lenvatinib

  • Paclitaxel

  • Erbitux

  • Docetaxel

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved